DNA monoclonal antibodies targeting checkpoint molecules

US11896654B2 · kind B2 · utility

Assignees

• The Trustees of the University of Pennsylvania · US
• The Wistar Institute of Anatomy and Biology · US
• Inovio Pharmaceuticals, Inc. · US

Inventors

• David B. Weiner · Yeadon, US
• Kar Muthumani · Cherry Hill, US
• Niranjan Y. Sardesai · Blue Bell, US

Key dates

• Filing date: May 5, 2017
• Grant date: Feb 13, 2024
• Expiry date: Jan 12, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets an immune checkpoint molecule. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.